| CAS ID: | 17230-88-5 |
| Molecular Formula: | C22H27NO2 |
| Molecular Weight: | 337.5 g/mol |
| Monoisotopic Mass: | 337.2042 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | WIN 17,757 | DANOCRINE | DANAZOL |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1 | See All |
| InChI Key: | POZRVZJJTULAOH-LHZXLZLDSA-N | |
| Smiles: | C[C@]12Cc3cnoc3C=C1CC[C@@H]4[C@@H]2CC[C@@]5(C)[C@H]4CC[C@@]5(O)C#C | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT00244569 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 26, 2005 | Last Verified | March 20, 2017 |
| Sponsor | Virginia Commonwealth University | ||
Trial Record 2
| ClinicalTrial ID | NCT03312400 | Disease | Pulmonary fibrosis |
| Phase | Phase 2 | Status | Recruiting |
| First Received | October 17, 2017 | Last Verified | February 8, 2019 |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) | ||
Trial Record 3
| ClinicalTrial ID | NCT03312400 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Recruiting |
| First Received | October 17, 2017 | Last Verified | February 8, 2019 |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) | ||
Trial Record 4
| ClinicalTrial ID | NCT01441037 | Disease | Pulmonary fibrosis |
| Phase | Phase 1,Phase 2 | Status | Completed |
| First Received | September 27, 2011 | Last Verified | August 15, 2018 |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) | ||
| PubChem: | 28417 |
| ChEMBL: | CHEMBL1479 |